Explore

Trendline Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Trendline Trendline
Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer
Trendline Trendline
Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial
Trendline Trendline
Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration
Trendline Trendline
IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358
Trendline Trendline
IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy
Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302
Trendline Trendline
Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma

Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma

Partner Therapeutics Gains FDA Approval for Bizengri in Treating Advanced Cholangiocarcinoma
Trendline Trendline
Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy

Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy

Anixa Biosciences Reports Positive Survival Data from Phase 1 Trial of Lira-cel Ovarian Cancer Therapy
Trendline Trendline
Ankyra Therapeutics Showcases Anchored Immunotherapy at PEGS Boston 2026

Ankyra Therapeutics Showcases Anchored Immunotherapy at PEGS Boston 2026

Ankyra Therapeutics Showcases Anchored Immunotherapy at PEGS Boston 2026
Trendline Trendline
Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026